NCT07174908View on ClinicalTrials.gov

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2030

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

IN10018 in combination with D-1553

IN10018 100mg QD PO and D-1553 600mg BID PO, 21days per cycle

DRUG

anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed

Tislelizumab 200mg Q3W IV + Carboplatin AUC 5 mg/mL/min or Cisplatin 75mg/m² Q3W IV+ Pemetrexed 500mg/m² Q3W IV

All Listed Sponsors
lead

InxMed (Shanghai) Co., Ltd.

INDUSTRY